Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0028 in Advanced Solid Tumors
NCT06223308Phase 2Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HB0028 in solid tumor, Cervical Cancer (CC), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Sep 2022; status: recruiting.
02
Drugs
HB0028
03
Conditions
solid tumorCervical Cancer (CC)
Beyond the preview
Go deeper on NCT06223308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223308.